header image

Safety First

At Octapharma, patient safety is critically important and is never left to chance. Our enviable history and proven track record are a function of a highly rigorous process that begins with our raw material, human plasma. All blood donors, collection centres, and donated blood are held to the highest standards. Once received in our facility, a highly precise and multi-stage virus inactivation process takes over before releasing finished goods into the marketplace.

 

Donors

Donors themselves must undergo a comprehensive up front and ongoing review process. Only donors with a registered identity in the form of a Social Insurance Number are allowed to donate. Prior to each donation, donors are assigned a unique ID, and registered in the Octapharma donor database. A deferral check is conducted, and a detailed health history is taken. An accredited healthcare professional then provides an overall assessment, and may choose to exclude any donor that does not meet the acceptance criteria. 

Plasma Collection Centres

In the USA and the EU, our plasma collection centres are routinely inspected and both FDA and EMEA approved. In Canada, collection is managed by Canadian Blood Services and Héma-Québec, and is subjected to Health Canada standards.

Donated Plasma Screening

Once received from the collection centres, all donated plasma undergoes individual unit testing for antibodies against HIV-1/2, HBV, HCV and syphilis. Plasma also undergoes PCR (NAT) testing for HIV, HBV, HCV and parvovirus B19. The result of this process is an exceptionally pure, high quality fresh frozen plasma (FFP) product.

Virus Inactivation/Prion Removal

  • Single FFP units are combined and retested for HBV, HIV-1/2, HCV, and B19.
  • Following this, approved plasma is subjected to the Solvent-Detergent process, which is the current gold standard for safety from highly infectious enveloped viruses.
  • A meticulous chromatography and filtration process or alternative process removes further viral contaminants including prions. The type of process used varies according to the product being produced but the end goal remains the same.
  • Finished products may be aseptically freeze dried into a powder form and placed into vials or packaged as solutions for infusion.
  • PermaHeat or an alternative process is applied as an effective means to inactivate both enveloped and non enveloped virus.
  • At last, finished goods are subjected to our rigorous scientific Quality Control process before being released into the market.